RxDoctor Payments Data

Eric Murch, DO

Family Medicine · Newton, NJNPI 1497203004

Payments from drug & device makers

$575in general payments, 2019–2025

Across 35 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$382
  • Amarin Pharma, Inc.$45
  • Exact Sciences$33
  • AstraZeneca$32
  • GSK$20
  • Kowa Pharmaceuticals America, Inc.$17
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk24$382
Amarin Pharma, Inc.3$45
Exact Sciences1$33
AstraZeneca2$32
GSK1$20
Kowa Pharmaceuticals America, Inc.1$17
Watermark Medical, Inc.1$16
Pfizer1$15
Lilly USA, LLC1$15

How this compares

$575 in reported general payments places this provider in the 55th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$354,764
Medicare patients
518
Services billed
4,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide113$134,063
RybelsusSemaglutide38$81,364
OzempicSemaglutide55$78,305
JardianceEmpagliflozin42$65,505
EliquisApixaban29$45,653
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$34,382
Nurtec OdtRimegepant Sulfate17$30,337
WegovySemaglutide16$21,088
TrulicityDulaglutide18$17,766
Icosapent Ethyl12$7,116
Atorvastatin Calcium573$6,297
Breo ElliptaFluticasone/Vilanterol11$5,635
Rosuvastatin Calcium449$5,019
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$4,978
Levothyroxine Sodium410$4,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Wegovy$382$180,758109 claims
Lilly USA, LLCMounjaro, Trulicity$15$151,829131 claims
PfizerEliquis, Nurtec Odt$15$75,99046 claims
GSKTrelegy Ellipta, Breo Ellipta$20$40,01741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Newton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →